EUVIMEDSkopri EUVIMED
ÜbersichtsarbeitOpen access · CC BY-NC-ND 4.0

Pancreatic Cancer Early Detection Biomarkers for High‐Risk Individuals: Insights From the PRECEDE Consortium

Christine Worthington, Maria Raitses-Gurevich, Giulio Innamorati, Phil A Hart, Thomas M Wilkie, Noam Tau, Dana Brin, Doron Yablecovitch, Ido Laish, Dove Keith, Kurt Giles, Jennifer B Permuth iD and 6 more

International Journal of Cancer · 2026-10-15 · 159 (8) · 1873-1883

DOI: 10.1002/ijc.70592 ↗

At a glance

Übersichtsarbeit in International Journal of Cancer, published online on 2026-06-15. Written by Christine Worthington and 17 co-authors. Institution: Division of Gastroenterology, Hepatology, and Nutrition, College of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA. Major MEDLINE topics: Pancreatic Neoplasms, Early Detection of Cancer, Biomarkers, Tumor, Carcinoma, Pancreatic Ductal. Cited 2 times so far (Crossref); 88 references. The full text is freely available (open access, CC BY-NC-ND 4.0).

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers due to its asymptomatic progression, late‐stage diagnosis, and treatment resistance. Efforts in early detection have centered on identifying imaging features and liquid biopsy biomarkers capable of detecting PDAC and its high‐grade precursors before clinical symptoms arise in patients at elevated risk of PDAC development. Classical imaging‐based surveillance strategies, aligned with current guidelines, form the foundation of screening high‐risk individuals, while organ‐specific fluid analyses—such as cyst fluid and pancreatic juice—offer promising complementary tools with enhanced specificity. Recent advances in radiomics, liquid biopsy, microbiome, and multi‐omics profiling are expanding the frontier of early detection. Despite advances, significant challenges persist. Precursor lesions are difficult to non‐invasively diagnose; are not radiologically or endosonographically visible, or cannot be definitively graded prior to resection. Though biomarkers show promise for early detection, they present unique challenges: early‐stage neoplasias release low levels of many biomarkers and thresholds for these biomarkers that define malignant transformation—and thus guide surgical intervention—remain poorly established. Multi‐institutional initiatives like the Pancreatic Cancer Early Detection consortium (PRECEDE) are critical to bridging discovery and clinical translation. Our international cohort study of high‐risk individuals was designed to discover and validate diagnostic biomarkers according to the PROBE study design. Continued collaboration, technological integration, and patient‐centered approaches are essential to transform early detection research into tangible survival benefits for those at risk of PDAC.

Subjects

MeSH terms (MEDLINE)

Pancreatic NeoplasmsEarly Detection of CancerBiomarkers, TumorCarcinoma, Pancreatic DuctalHumansLiquid Biopsy

Author keywords

biomarkersearly detectionimagingliquid biopsypancreatic cancerscreening

Substances

Biomarkers, Tumor

Authors and institutions

  • Division of Gastroenterology, Hepatology, and Nutrition, College of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
  • The Jusidman Cancer Center, Chaim Sheba Medical Center, Tel HaShomer Hospital, Ramat Gan, Israel.
  • Laboratory of Translational Surgery, Department of Surgery, Dentistry, Maternity and Infant, University of Verona, Verona, Italy.
  • Division of Gastroenterology, Hepatology, and Nutrition, College of Medicine, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.
  • Pharmacology Department, UT Southwestern Medical Center, Dallas, Texas, USA.
  • Department of Diagnostic Imaging, Chaim Sheba Medical Center, Tel HaShomer Hospital, Tel Aviv University, Ramat Gan, Israel.

ORCID profiles: Jennifer B Permuth, Julie Earl

Cite

APA

Worthington, C., Raitses-Gurevich, M., Innamorati, G., Hart, P. A., Wilkie, T. M., Tau, N., Brin, D., Yablecovitch, D., Laish, I., Keith, D., Giles, K., Permuth, J. B., Simeone, D. M., Zogopoulos, G., Brand, R. E., Graff, J. J., Earl, J., & PRECEDE Consortium (2026). Pancreatic Cancer Early Detection Biomarkers for High‐Risk Individuals: Insights From the PRECEDE Consortium. International Journal of Cancer, 159(8), 1873-1883. https://doi.org/10.1002/ijc.70592

Vancouver

Worthington C, Raitses-Gurevich M, Innamorati G, Hart PA, Wilkie TM, Tau N, et al. Pancreatic Cancer Early Detection Biomarkers for High‐Risk Individuals: Insights From the PRECEDE Consortium. International Journal of Cancer. 2026;159(8):1873-1883. doi:10.1002/ijc.70592

BibTeX
@article{Worthington2026,
  author = {Worthington, Christine and Raitses-Gurevich, Maria and Innamorati, Giulio and Hart, Phil A and Wilkie, Thomas M and Tau, Noam and Brin, Dana and Yablecovitch, Doron and Laish, Ido and Keith, Dove and Giles, Kurt and Permuth, Jennifer B and Simeone, Diane M and Zogopoulos, George and Brand, Randall E and Graff, John J and Earl, Julie and PRECEDE Consortium, PRECEDE Consortium},
  title = {Pancreatic Cancer Early Detection Biomarkers for High‐Risk Individuals: Insights From the PRECEDE Consortium},
  journal = {International Journal of Cancer},
  year = {2026},
  volume = {159},
  number = {8},
  pages = {1873--1883},
  doi = {10.1002/ijc.70592}
}
Start for free →